Pre-Pro-MS
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Prebiotics and Probiotics supplementation
- peripheral blood withdrawal
- Transcranial Magnetic Stimulation (TMS)
Placebo or sham
- Placebo supplementation
What it measured
Main measures
Changes in gut microbiota diversity or composition
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in microbiota metabolites - indican
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in microbiota metabolites - skatole
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in serum glutamate
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in serum synaptotoxic miRNAs
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in plasma inflammatory molecules
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in immunophenotype
T0 vs T12 (months), Pre-Pro versus Placebo groups
Immune responseChanges in T cell metabolic asset
T0 vs T12 (months), Pre-Pro versus Placebo groups
Immune response
Other measures (17)
Changes in neurophysiological response
T0 vs T12 (months), Pre-Pro versus Placebo groups
Myelin repairNerve conduction testsChanges in clinical disability
T0 vs T12 (months), Pre-Pro versus Placebo groups
Disability progressionChanges in lower extremity function
T0 vs T12 (months), Pre-Pro versus Placebo groups
Disability progressionWalking and mobilityChanges in upper extremity function
T0 vs T12 (months), Pre-Pro versus Placebo groups
Disability progressionArm and hand functionChanges in quality of life
T0 vs T12 (months), Pre-Pro versus Placebo groups
Thinking and memoryFatigueBladder, bowel and sexual functionQuality of life (reported by participants)Assessment of mild to moderate dysfunctions
T0 vs T12 (months), Pre-Pro versus Placebo groups
Disability progressionThinking and memoryChanges in global cognitive disability
T0 vs T12 (months), Pre-Pro versus Placebo groups
Thinking and memoryAssessment of attention and information processing speed
T0 vs T12 (months), Pre-Pro versus Placebo groups
Thinking and memoryChanges in phonemic verbal fluency
T0 vs T12 (months), Pre-Pro versus Placebo groups
Changes in verbal memory performance
T0 vs T12 (months), Pre-Pro versus Placebo groups
Thinking and memory
Who could take part
Relapsing MS · 18 to 65
Inclusion Criteria: * RRMS diagnosis, as Polman et al 2011. Ann Neurol. PMID: 21387374 * Age \<= 18 and => 65 years * EDSS score \<= 7 * Disease duration \< 10 years * On DMF or Ocrelizumab treatment from at least 3 months * No corticosteroid administration in the previous month * Ability to provide written informed consent. Exclusion Criteria: * Adverse effects to gadolinium * Blood count basal alteration * Pregnant or lactating women * Vegetarians or vegans * Taking antibiotics, any product or supplement containing probiotics, Omega 3 or other antioxidant supplements within 30 days prior to inclusion * History of food allergies or food intolerance * Clinically significant medical condition other than MS, (latent infections, other autoimmune disease) * Diagnosis of past eating disorders (anorexia, bulimia, or binge eating) or relevant psychiatric disorders.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Inflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis.
Papers
Background
Mandolesi G, Gentile A, Musella A, Fresegna D, De Vito F, Bullitta S, Sepman H, Marfia GA, Centonze D. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol. 2015 Dec;11(12):711-24. doi: 10.1038/nrneurol.2015.222. Epub 2015 Nov 20.Background
De Vito F, Musella A, Fresegna D, Rizzo FR, Gentile A, Stampanoni Bassi M, Gilio L, Buttari F, Procaccini C, Colamatteo A, Bullitta S, Guadalupi L, Caioli S, Vanni V, Balletta S, Sanna K, Bruno A, Dolcetti E, Furlan R, Finardi A, Licursi V, Drulovic J, Pekmezovic T, Fusco C, Bruzzaniti S, Hornstein E, Uccelli A, Salvetti M, Matarese G, Centonze D, Mandolesi G. MiR-142-3p regulates synaptopathy-driBackground
Stampanoni Bassi M, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, Micillo T, De Rosa V, Sica F, Furlan R, Finardi A, Fantozzi R, Storto M, Bellantonio P, Pirollo P, Di Lemme S, Musella A, Mandolesi G, Centonze D, Matarese G. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler. 2020 Sep;26(10):1237-1246. doi: 10.1177/1352458519853473. Epub 2019 Jun 4.Background
Buckman LB, Hasty AH, Flaherty DK, Buckman CT, Thompson MM, Matlock BK, Weller K, Ellacott KL. Obesity induced by a high-fat diet is associated with increased immune cell entry into the central nervous system. Brain Behav Immun. 2014 Jan;35:33-42. doi: 10.1016/j.bbi.2013.06.007. Epub 2013 Jul 4.Background
Haase S, Wilck N, Haghikia A, Gold R, Mueller DN, Linker RA. The role of the gut microbiota and microbial metabolites in neuroinflammation. Eur J Immunol. 2020 Dec;50(12):1863-1870. doi: 10.1002/eji.201847807. Epub 2020 Dec 7.Background
Mirashrafi S, Hejazi Taghanaki SZ, Sarlak F, Moravejolahkami AR, Hojjati Kermani MA, Haratian M. Effect of probiotics supplementation on disease progression, depression, general health, and anthropometric measurements in relapsing-remitting multiple sclerosis patients: A systematic review and meta-analysis of clinical trials. Int J Clin Pract. 2021 Nov;75(11):e14724. doi: 10.1111/ijcp.14724. EpubBackground
Siracusa F, Schaltenberg N, Villablanca EJ, Huber S, Gagliani N. Dietary Habits and Intestinal Immunity: From Food Intake to CD4+ T H Cells. Front Immunol. 2019 Jan 15;9:3177. doi: 10.3389/fimmu.2018.03177. eCollection 2018.Background
Valizadeh S, Majdi Seghinsara A, Maleki Chollou K, Bahadori A, Abbaszadeh S, Taghdir M, Behniafar H, Riahi SM. The efficacy of probiotics in experimental autoimmune encephalomyelitis (an animal model for MS): a systematic review and meta-analysis. Lett Appl Microbiol. 2021 Oct;73(4):408-417. doi: 10.1111/lam.13543. Epub 2021 Aug 11.Background
Sichetti M, De Marco S, Pagiotti R, Traina G, Pietrella D. Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition. 2018 Sep;53:95-102. doi: 10.1016/j.nut.2018.02.005. Epub 2018 Feb 14.
Loading reviews and guidelines…
Related trials
- PRO-RRMS
Not a drug-phase study · Completed
No result found
- Investigating the Effects of Hydroxyvitamin D3 on Multipl…
Phase 4 · Status unknown
No result found
- EDQ
Not a drug-phase study · Running, not recruiting
Still running
- MS
Not a drug-phase study · Completed
Result in a paper, not read yet
- Longitudinal Effect of Vitamin D3 Replacement on Cognitiv…
Not a drug-phase study · Status unknown
No result found
- Melatonin in Patients With Multiple Sclerosis (MS).
Early phase 1 · Completed
Results posted, no main test reported
History
Started
Jul 2023
Main results due
Nov 2024
Finished
May 2026
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error